Latest Information Update: 22 Feb 2010
$50 / €47 *
At a glance
- Originator IDM S.A.
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ovarian cancer
Most Recent Events
- 08 Apr 2005 Suspended - Preclinical for Ovarian cancer in France (Parenteral)
- 02 Dec 2003 Preclinical trials in Ovarian cancer in France (Parenteral)